Article Text

Download PDFPDF
Fingolimod (Gilenya) and melanoma
  1. Christopher Lee Robinson1,
  2. Mary Guo2
  1. 1Department of Dermatology, Saint Louis University School of Medicine, Saint Louis, Missouri, USA
  2. 2Department of Dermatology, St. Louis University, St. Louis, Missouri, USA
  1. Correspondence to Dr Mary Guo, aguo{at}


The Food and Drug Administration (FDA) had approved fingolimod usage for multiple sclerosis in 2010. Melanoma after the usage of fingolimod immunomodulation was reported rarely in clinical trials, and only two case reports exist in the published literature, both occurring in Europe. Most of the incidences reported in clinical trials were in-situ, whereas both case reports were of malignant melanoma. Fingolimod has been found to inhibit metastatic melanoma growth in a mouse model that depends on vascular endothelial growth factor (VEGF)-induced angiogenesis for metastasis. However, there are numerous pathways of angiogenesis and tumour growth found in vivo by which melanoma can expand that do not mandate VEGF. We report a case of superficial spreading malignant melanoma occurring after fingolimod therapy in the USA.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors Data interpretation, drafting of the manuscript and review of the literature first performed by CLR. Revising the manuscript critically for important intellectual content, patient consenting, and correspondence were carried out by MG.

  • Competing interests None declared.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.